Annexon, Inc. (ANNX): R&D Expense
$184.70M
Year ended 2025-12-31
$174.74M
Trailing 12 months to 2026-06-30
+18.0%
3-year compound annual growth
+30.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $184.70M | +54.6% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $119.45M | +5.0% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $113.76M | +1.1% | 2025-03-03, From 2023-01-01 |
| 2022-12-31 | $112.50M | +12.4% | 2024-03-26, From 2022-01-01 |
| 2021-12-31 | $100.07M | +103.1% | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | $49.27M | +100.9% | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $24.52M | n/a | 2021-03-25, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Annexon, Inc. (ANNX) | 2025-12-31 | $184.70M | +54.6% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $44.49M | +11.3% |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $51.52M | +34.1% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $66.43M | -19.2% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $117.33M | -3.0% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $106.74M | -18.8% |
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $102.93M | +28.5% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $112.21M | -42.5% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $12.74M | -69.7% |
Compare ANNX, TNXP, CTNM, ALT side by side · Screen every company in Pharmaceutical Preparations ↗